Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
10-day versus 14-day bismuth-containing quadruple therapy for Helicobacter pylori eradication in Chongqing
ChiCTR-IPR-15005963Phase 4Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esomeprazole, bismuth subsalicylate, clarithromycin and amoxicillin in Helicobacter pylori infection (2 arms), sponsored by Xinqiao Hospital. Primary endpoint: Helicobacter pylori eradication rate. Started Jan 2015; status: recruiting.
02
Drugs
esomeprazolebismuth subsalicylateclarithromycinamoxicillin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR-IPR-15005963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15005963.